Results 21 to 30 of about 11,480 (212)

Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy ...
Jie-Ning Wang   +6 more
doaj   +1 more source

Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis. [PDF]

open access: yesPLoS ONE, 2011
BACKGROUND: It has been controversial whether abciximab offered additional benefits for diabetic patients who underwent percutaneous coronary intervention (PCI) with thienopyridines loading.
Yihua Wu   +6 more
doaj   +1 more source

Intravenous abciximab as a rescue therapy for immediate reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients

open access: yesPlatelets, 2022
Immediate reocclusion after mechanical thrombectomy (MT) for acute ischemic stroke (AIS) is a rare but devastating condition associated with poor functional outcome.
François Delvoye   +19 more
doaj   +1 more source

Alveolar Hemorrhage during Abciximab Infusion

open access: yesJournal of Tehran University Heart Center, 2021
Not ...
Yavuzer Koza   +3 more
doaj   +1 more source

Mechanical clot dissolution technique for surgical clip-related occlusions: An emergent triple-step approach

open access: yesBrain Circulation, 2021
Cerebral ischemia following clipping of cerebral aneurysms constitutes major cause of morbidity and mortality. Clip-related injury to vessel, postoperative clip rotation, prolonged temporary occlusion, intraoperative rupture, and vasospasm are some ...
Chirag Jain   +3 more
doaj   +1 more source

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y<sub>12</sub> Inhibitor Prescribing. [PDF]

open access: yesClin Pharmacol Ther
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Springer AN   +14 more
europepmc   +2 more sources

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report

open access: yesSão Paulo Medical Journal, 2017
CONTEXT: There are no reports on cases of subconjunctival hemorrhage due to use of glycoprotein IIb/IIIa inhibitors. In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab.
Selim Kul, Muhammet Raşit Sayın
doaj   +1 more source

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio

open access: yesBMC Cardiovascular Disorders, 2006
Background The significant reduction of angiographic restenosis rates in the ISAR-SWEET study (intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetes) raises the question of ...
Baur Regine   +4 more
doaj   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

open access: yes, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast   +66 more
core   +2 more sources

Quantitative structural mechanobiology of platelet-driven blood clot contraction. [PDF]

open access: yes, 2017
Blood clot contraction plays an important role in prevention of bleeding and in thrombotic disorders. Here, we unveil and quantify the structural mechanisms of clot contraction at the level of single platelets.
Alber, Mark S   +3 more
core   +2 more sources

Home - About - Disclaimer - Privacy